Methods and systems for predicting colorectal cancer incidence and mortality
Disclosed are methods and systems that uses GlycA concentration in biosamples to evaluate risks of CRC incidence and mortality.
1. A method of measuring GlycA concentration, the method comprising:
(a) providing a sample from a subject with colorectal cancer; and,
(b) using NMR, determining if the GlycA concentration in the sample is at least 370 μmol/L.
2. The method of claim 1 , wherein the subject is not showing symptoms associated with the colorectal cancer.
3. The method of claim 1 , wherein step (b) further comprises, using the NMR, determining if the GlycA concentration in the sample is in a third quartile, a fourth quartile, or a third tertile of a population norm.
4. The method of claim 1 , wherein step (b) comprises, using the NMR, determining if the GlycA concentration in the sample is at least about 400 μmol/L or at least about 415 μmol/L.
5. A method of measuring GlycA concentration, the method comprising:
providing a sample from a subject with colorectal cancer;
measuring by NMR if the GlycA concentration in the sample is at least 370 μmol/L; and,
measuring concentration in the sample of at least one acute phase protein and/or at least one inflammatory protein and/or at least one lipoprotein.
6. The method of claim 5 , wherein the at least one acute phase protein comprises one of fibrinogen, hsCRP or sICAM-1 and/or the at least one lipoprotein comprises ApoA1.
7. The method of claim 5 , wherein the measuring by the NMR further comprises determining if the GlycA concentration in the sample is in a third quartile, a fourth quartile, or a third tertile of a population norm.
8. The method of claim 5 , wherein the measuring by the NMR comprises measuring if the GlycA concentration in the sample is at least about 400 μmol/L or at least about 415 μmon.
9. A method of measuring GlycA concentration comprising:
(a) providing a sample from a subject with colorectal cancer, and
(b) measuring by NMR if the GlycA concentration in the sample is at least 370 μmol/L and is in a third quartile, a fourth quartile, or a third tertile of a population norm.
10. The method of claim 9 , wherein step (b) comprises measuring by the NMR if the GlycA concentration in the sample is at least about 400 μmol/L or at least about 415 μmol/L.
11. The method of claim 1 , wherein the sample is a whole blood sample, a serum sample, or a plasma sample.
12. A method for measuring GlycA change during a colorectal cancer (“CRC”) treatment for a drug-treated subject with colorectal cancer, comprising:
(a) obtaining a first sample and a second sample from the drug-treated subject with colorectal cancer, wherein the first sample and the second sample are obtained at a first time point and a second time point during a treatment period; and
(b) measuring GlycA concentration in each of the first sample and the second sample by NMR.
13. The method of claim 12 , wherein the first sample and the second sample is a whole blood sample, a serum sample, or a plasma sample.
14. The method of claim 5 , wherein the sample is a whole blood sample, a serum sample, or a plasma sample.
15. The method of claim 9 , wherein the sample is a whole blood sample, a serum sample, or a plasma sample.
16. The method of claim 5 , wherein the wherein the subject is not showing symptoms associated with the colorectal cancer.
17. The method of claim 9 , wherein the subject is not showing symptoms associated with the colorectal cancer.